Comparing the Effectiveness of Test and Treat Approaches with Doxycycline or Moxidectin plus Albendazole versus Mass Drug Administration with Ivermectin plus Albendazole for Targeted Elimination of Lymphatic Filariasis in Ghana and Tanzania - aPhase III Clinical Trial

开始日期2024-10-01

申办/合作机构-

NCT06188715 / Completed临床3期IIT

Efficacy and Safety of Moxidectin-albendazole Combination for Trichuris Trichiura Infections in School-aged Children: a Double-blind Randomised Controlled Superiority Trial

This study is a double-blind randomized controlled superiority trial aiming at providing evidence on the efficacy and safety of co-administered moxidectin and albendazole compared to albendazole monotherapy in school-aged children (SAC; aged 6-12 years) infected with whipworm (Trichuris trichiura) on Pemba Island, Tanzania. Additionally, evidence on the safety profile of moxidectin-albendazole combination in this age group will be substantiated using a placebo (and albendazole) only arm. To date, this has only been established in adolescents (aged 16-18 years), who might present different symptoms or symptom severity compared with SAC.
As measure of efficacy of the treatment the cure rate (percentage of eggpositive subjects at baseline who become egg-negative after treatment) will be determined 14-21 days post-treatment.

开始日期2024-05-14

申办/合作机构

Swiss Tropical & Public Health Institute

100 项与莫昔克丁相关的临床结果

登录后查看更多信息

100 项与莫昔克丁相关的转化医学

登录后查看更多信息

100 项与莫昔克丁相关的专利（医药）

登录后查看更多信息

1,270

项与莫昔克丁相关的文献（医药）

2024-12-01·International Journal for Parasitology: Drugs and Drug Resistance

Macrocyclic lactones and ectoparasites control in livestock: Efficacy, drug resistance and therapeutic challenges

Review

作者: Miró, V ; Lanusse, C ; Canton, C ; Nava, S ; Alvarez, L ; Lifschitz, A

Macrocyclic lactones (MLs) are the cornerstone of parasite control in livestock due to their broad-spectrum activity against endo (nematodes) and ecto (lice, ticks, mites) parasites. These molecules, introduced into the veterinary pharmaceutical market 40 years ago, have substantially improved animal welfare and productivity by offering extended high efficacy, reducing treatment frequency, and displaying a favorable safety profile. However, their widespread and intensive use has led to a significant challenge nowadays: the development of parasite resistance. This review focuses on the critical link between drug pharmacokinetics (variation in concentration profiles and exposure over time) and pharmacodynamics (drug efficacy) and the ability of both avermectin and milbemycin MLs families to control livestock ectoparasites. This review discusses the integrated assessment of drug behavior in the host, its diffusion into target parasites, and the impact of different pharmaceutical formulations on enhancing drug delivery to infection sites. These are considered critical research/development areas to optimize the use of MLs, preventing treatment failures and finally extending the lifespan of these essential pharmaceutical ingredients. Finally, the importance of the rational use of MLs, guided by parasite epidemiology and pharmacological knowledge, is emphasized as a key strategy to preserve the antiparasitic efficacy of these still very useful molecules.

2024-12-01·Applied Microbiology and Biotechnology

Moxidectin elevates Candida albicans ergosterol levels to synergize with polyenes against oral candidiasis

Article

作者: Gou, Lichen ; Zhou, Xinxuan ; Zou, Jing ; Shen, Jiawei ; Zhou, Xuedong ; Liu, Yaqi ; Ren, Biao ; Chen, Ding ; Zhou, Yuan ; Liao, Ga ; Wang, Jiannan ; Ye, Xingchen ; Liao, Binyou

Candida albicans, the most common opportunistic pathogenic fungus, is also the main pathogenic organism for oral candidiasis. This condition is particularly prevalent among the elderly, children, and individuals undergoing radiotherapy or suffering from HIV. The lack of new antifungal drugs, and drug resistance coupled with the side effects of current antifungal agents have increased the challenges of clinical antifungal therapies. Polyenes, including amphotericin B and nystatin, are clinical fungicidal drugs, however, their side effects and low solubility have limited their clinical applications. Here, we identified that moxidectin, a novel approved antiparasitic agent, could synergize with both amphotericin B and nystatin to inhibit the growth and biofilm formation of Candida albicans including 60 clinical isolates. The transcriptome and RT-PCR analysis indicated that moxidectin activated the biosynthesis pathway of ergosterol, the direct target of polyenes, further being verified by the loss of the synergistic activities with polyenes against ergosterol pathway mutants, including Δ/Δerg3, Δ/Δerg11 and Δ/Δerg3 Δ/Δerg11. Moxidectin was then confirmed to elevate the ergosterol biosynthesis levels of C. albicans and enhance the binding between cells and polyenes. In a mouse oral candidiasis model, moxidectin combined with low dosages of polyenes to significantly reduce the infection area, colonization of C. albicans and the inflammatory degree of tongue mucosa. Our study originally demonstrated that moxidectin could activate the ergosterol biosynthesis then elevate the ergosterol contents to enhance the antifungal effects of polyenes against C. albicans and its infections. Moxidectin can serve as the candidate potentiator of polyenes for further clinical practice. KEY POINTS: • Moxidectin synergized with polyenes against Candida albicans. • Moxidectin activated the ergosterol biosynthesis of Candida albicans. • Moxidectin combined with polyenes to effectively combat oral candidiasis in mice.

2024-12-01·International Journal for Parasitology: Parasites and Wildlife

Identification and management of infections caused by Giardia sp., Trichuris sp. and Demodex sp. in captive Brazilian porcupines (Coendou prehensilis)

Article

作者: Frey, Caroline F ; Frey, Caroline F. ; Moré, Gastón ; Gliga, Diana S ; Rüegg-van den Broek, Peggy ; Glardon, Olivier J ; Basso, Walter ; Gliga, Diana S. ; Glardon, Olivier J.

The Brazilian porcupine (Coendou prehensilis, Rodentia, Erethizontidae) is an arboreal South American nocturnal rodent. Switzerland is home to one of the largest captive colonies in Europe. In June 2022, most of the animals in this colony showed severe diarrhoea, and Giardia sp. cysts were detected. All the animals were treated with metronidazole (75 mg/animal/day orally) for five days, repeating after two weeks. The diarrhoea continued, sometimes containing blood, and further analyses revealed Giardia sp. cysts and Trichuris sp. eggs with a particular undulating eggshell in pooled samples. The soil layer of some enclosures was removed to thoroughly clean and disinfect the underlying concrete floor. The animals were treated with fenbendazole (50 mg/kg/day orally) for 5 days repeating after three days. Giardia sp. cysts were not further detected. However, Trichuris sp. eggs were detected in branch bark samples and in six animals 2-3 months after treatment. The treatment with fenbendazole was repeated and no further Trichuris sp. eggs were detected. A 18S rRNA fragment consensus sequence showed 98.58% identity with Trichuris fossor. The Trichuris sp. in C. prehensilis may represent a new species, specific for arboreal porcupines. Demodex mites were observed in faecal flotations and thereafter in skin scrapings from five animals (four of them being family-related). A 16S consensus sequence showed 86.4% identity with other Demodex species. The animals were initially treated with moxidectin (0.4 and 0.8 mg/kg orally) and afterwards with sarolaner (10 mg/animal) but the treatments were not completely effective since in control scrapings, two animals evidenced few non-motile mites. An individual susceptibility and poor immunological control of the infection is suggested. Treatment with fenbendazole was effective against Giardia sp. and Trichuris sp. infections; however, reinfections may occur if the enclosures and tree branches are not deep cleaned and disinfected or replaced.

项与莫昔克丁相关的新闻（医药）

2024-08-15

·PRNewswire

Credelio® (lotilaner) Kills Ticks 2x as Fast as Simparica TRIO® (sarolaner, moxidectin and pyrantel) and NexGard® (afoxolaner)

Study finds that the aggressive lone star tick is no match for Credelio GREENFIELD, Ind., Aug. 15, 2024 /PRNewswire/ -- Parasites & Vectors, a leading peer-reviewed journal focused on parasites and vector-borne pathogens published the results of a head-to-head study demonstrating that Credelio, a prescription flea and tick protection product from Elanco Animal Health, has the fastest initial speed of tick kill in just 12 hours and sustains that advantage throughout the dosing interval.1,2,3 According to the Centers for Disease Control (CDC), during 2019 – 2022, state and local health departments reported more than 45,000 human cases of tickborne disease to CDC.4 The Companion Animal Parasite Council (CAPC) recommends using products on pets that kill and/or repel ticks before pathogens are transmitted.5 Continue Reading Dr. Kathryn Reif, Bailey-Goodwin Endowed Associate Professor in Parasitology at Auburn University, highlights the importance of the study findings. The 2023 head-to-head study compared three popular prescription flea and tick treatment products for dogs, Credelio (lotilaner), Simparica TRIO (sarolaner, moxidectin, pyrantel), and NexGard (afoxolaner), tracking the comparative data for the relative speeds of kill of Amblyomma americanum (lone star tick). The 2023 head-to-head study compared three popular prescription flea and tick treatment products for dogs, Credelio (lotilaner), Simparica TRIO (sarolaner, moxidectin, pyrantel), and NexGard (afoxolaner), tracking the comparative data for the relative speeds of kill of Amblyomma americanum (lone star tick) – an aggressive and expanding tick found in the United States that is one of the hardest to kill. Not only is this tick hard to kill, but it can also transmit dangerous disease-causing pathogens to pets and people. The CDC recently provided in-depth tick surveillance information regarding the aggressive nature of the lone star tick that can bite humans and transmit bacterial and viral pathogens, as well as cause alpha-gal syndrome (red meat allergy).6 "The results of this head-to-head study establishes Credelio as the front runner in speed of tick kill in prescription flea and tick treatment products for dogs.1 This is important because the longer a tick is attached, the greater the risk of pathogen transmission," said Dr. Kathryn Reif, Bailey-Goodwin Endowed Associate Professor in Parasitology at Auburn University. "These pathogens can cause serious diseases, such as Rocky Mountain Spotted Fever and ehrlichiosis, so it is critical that veterinarians talk with pet owners about year-round parasite protection. Credelio's rapid and sustained speed of tick kill helps protect pets against pathogen-carrying ticks which can result in dangerous diseases."1 The study included dogs that were randomly allocated to one of four treatment groups: Credelio, Simparica TRIO, NexGard or untreated control. Live tick counts were performed on dogs by blinded investigators during regular intervals.1 The study results found that by all 12-hour evaluation intervals, only the Credelio group significantly reduced lone star ticks as compared to the untreated control group. The study observed that the Simparica TRIO and NexGard groups were not significantly different from the untreated control group by any of the 12-hour evaluation intervals. The study also showed that Credelio significantly reduced ticks at all 12- and 24-hour evaluation time points and only Credelio provides a rapid speed of kill throughout the entire month-long treatment period.1,2,3 Of the evaluated products, only Credelio killed ticks as fast at the end of the month as at the beginning of the month. "This study sets Credelio apart from competitors as it maintains a rapid speed of tick kill throughout the entire monthly dosing period," said David Gosche, DVM, Elanco Sr. Director of Technical Marketing.1,2,3 "This product maintains consistent levels of efficacy in tick kill throughout the month, outperforming the competitors tested." 1,2,3 Learn more about Credelio for dogs here. To read the full study findings, click here. ABOUT ELANCO Elanco Animal Health Incorporated (NYSE: ELAN) is a global leader in animal health dedicated to innovating and delivering products and services to prevent and treat disease in farm animals and pets, creating value for farmers, pet owners, veterinarians, stakeholders, and society as a whole. With nearly 70 years of animal health heritage, we are committed to helping our customers improve the health of animals in their care, while also making a meaningful impact on our local and global communities. At Elanco, we are driven by our vision of Food and Companionship Enriching Life and our Elanco Healthy Purpose™ Sustainability Initiatives –all to advance the health of animals, people, and the planet. CREDELIO INDICATIONS Credelio kills adult fleas and is indicated for the treatment and prevention of flea infestations (Ctenocephalides felis) and the treatment and control of tick infestations [Amblyomma americanum (lone star tick), Dermacentor variabilis (American dog tick), Ixodes scapularis (black-legged tick) and Rhipicephalus sanguineus (brown dog tick)] for one month in dogs and puppies 8 weeks of age and older and weighing 4.4 pounds or greater. CREDELIO IMPORTANT SAFETY INFORMATION Lotilaner is a member of the isoxazoline class. This class has been associated with neurologic adverse reactions including tremors, ataxia, and seizures. Seizures have been reported in dogs receiving this class of drugs, even in dogs without a history of seizures. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of Credelio in breeding, pregnant or lactating dogs has not been evaluated. The most frequently reported adverse reactions are weight loss, elevated blood urea nitrogen, polyuria, and diarrhea. For full prescribing information see Credelio package insert. NexGard is a registered trademark of Boehringer Ingelheim Animal Health USA Inc. Simparica TRIO is a registered trademark of Zoetis Services LLC. Credelio, Elanco and the diagonal bar logo are trademarks of Elanco or its affiliates. Other company and product names are trademarks of their respective owners. © 2024 Elanco or its affiliates PM-US-24-1168 1 Ambylomma americanum (lone star tick) 2 Reif KE, Kollasch TM, Neilson JC, Herrin BH, Ryan WG, Bell MC, Beltz MS, Dryden MW, Jesudoss Chelladurai JRJ, Miller KR, Sutherland CJ. Comparative speed of kill provided by lotilaner (Credelio™), sarolaner (Simparica Trio™), and afoxolaner (NexGard™) to control Amblyomma americanum infestations on dogs. Parasite Vectors. 2024 Jul 20;17(1):313. 3 Based on the time to statistical significance vs control in a single study on days 21 and 28 for reinfestations. 4 Centers for Disease Control and Prevention. (n.d.). Tickborne Disease Surveillance Data Summary. Centers for Disease Control and Prevention. Retrieved August 8, 2024, from 5 Companion Animal Parasite Council | 2023 Annual Pet Parasite Forecasts (capcvet.org) 6 Centers for Disease Control and Prevention. (n.d.). Where Ticks Live. Centers for Disease Control and Prevention. Retrieved August 8, 2024, from Investor Contact: Katy Grissom (317) 273-9284 [email protected] Media Contact: Season Solorio (765) 316-0233 [email protected] SOURCE Elanco Animal Health

临床结果临床研究

2024-05-21

·药通社

国产宠物药2.0时代：怪圈

万人展会！一次性看现行法规下如何办理B证、MAH立项思路及案例、吸入制剂研发思路等……宠物药界，正掀起一场前所未有的变革风暴。（接上篇：人药变成宠物药，价格可以翻40倍）曾几何时，国产宠物药备受诟病，疫苗领域更是步履蹒跚。然而，就在市场似乎已经定型之际，转折却悄然而至：疫情无意之间为国内疫苗企业开启了一扇翻盘之门。妙三多代理商们的”骚操作“，彻底动摇了中国市场的天平，让监管打开快速审批大门的同时，也让市场对国产疫苗的期待与需求达到了峰值。国产猫三联的大量涌入，彻底颠覆了价格体系：曾经天价难求的妙三多，如今百元能打满三针。国内厂家获批不断，线上价格战更是激烈至极。来源 | 公司公告、长江证券研究所如今如何破局？国内入局和没入局的玩家都陷入了迷茫。那么我们放眼国际：硕腾以22%的市占率独占鳌头，稳坐全球动保行业之巅。硕腾是如何在如此激烈的市场竞争中脱颖而出？稳坐全球动保行业的王者之位？产品策略：穷则变，变则通，通则久对比其他头部动保企业，硕腾的产品矩阵最为全面。图 | 2022年硕腾不同品类宠物单品应收规模及占比来源 | 公司公告、长江证券研究所产品端与传统动保企业不同，硕腾在高度竞争品类和新兴品类两种产品策略上采取了差异化的打法：——对于高度竞争品类，硕腾会通过“微迭代”的方式来保持竞争力。这种策略尤其适用于产品市场规模庞大，属性更偏向日常消费品，且同质性较高的产品。如何理解微迭代？所谓“迭代”，基本围绕三个方向：1、提高安全性；2、扩宽适应症；3、提升使用体验。所谓“微”，就是不求一步登天，而是在市场精准把控之下，慢慢地对产品进行精雕细琢，每次只比竞品更好"一点"，积小胜为大胜。举个最典型的例子：硕腾的传统强项——驱虫药。驱虫作为宠物医药中规模最大的品类，竞争激烈从而导致产品同质性较强。由于驱虫产品本身技术壁垒不强，所以硕腾将驱虫药主要迭代方向定位为：“适应症增加+性价比”。1999年硕腾推出其革命性驱虫单品大宠爱，这是FDA首个批准的预防心丝虫和跳蚤感染的外用药，其内外同驱的杀虫效果，让大宠爱迅速在市场上霸占一席之地。然而，在激烈的市场竞争中，大宠爱一度被勃林格的超可信所超越。为了重夺市场份额，2015年，硕腾对产品进行了迭代，推出了外驱咀嚼片欣庞克。但这次迭代因适应症范围有限而成效平平。不满足于现状，硕腾再度对欣庞克进行了精准的配方升级，加入莫昔克丁和噻嘧啶两种成分，于2019年推出了欣庞克Trio。这款升级版产品直接对标勃林格的超可信，仅在适应症上新增了一种蜱虫的驱赶效果，并微调以肉味咀嚼片的形式提升了用户体验。通过这种策略性的微迭代，硕腾的驱虫药品从全球排名中第四直接飙升至第二，成就了其在驱虫品类的领导地位。目前国内做的比较成功的有瑞普生物的莫普欣、海正动保的莫爱佳，也是因为合计适应症数量和外资产品无显著差距，但更具性价比，因此在上市一年后已发展为销售额千万级单品。010203——对于新兴品类，硕腾则采取激进地进行颠覆性创新，以期在市场的制高点上占据一席之地。最为典型的例子是皮肤药和抗炎药。在皮肤药市场，硕腾以惊人的95%全球市场份额傲视群雄（2022）。| 犬特应性皮炎症状硕腾入局之前，市场上针对犬特应性皮炎症状的治疗产品，基本被礼蓝的阿托皮卡和泼尼松龙所包圆。然而，阿托皮卡虽然疗效持久，却存在给药困难的问题；而泼尼松龙虽然能迅速缓解症状，却伴随着巨大的副作用。于是，硕腾迅速推出了其创新产品艾博克和赛妥敏，艾博克能够在短短4小时内快速缓解过敏性瘙痒，其起效速度远超阿托皮卡，同时采用便于宠物主人喂食的咀嚼片形式，副作用也显著降低。赛妥敏则结合了先进的单克隆抗体技术，不仅扩大了作用对象，还进一步减轻了产品的副作用。| 骨关节抗炎药面对传统抗炎药普遍存在的副作用问题，硕腾在1997年推出了第一款骨关节抗炎药瑞莫迪，首次将治疗人类关节炎的非甾体抗炎药应用于宠物犬，有效缓解了老年犬的骨关节慢性疼痛。随着单克隆抗体疗法的兴起，硕腾又迅速布局，于2017年收购了专注于单克隆抗体疗法的公司Nexvet，并在2022年推出了首个猫犬单克隆抗体骨关节炎抗炎药索伦西亚与利布雷拉。与传统非甾体抗炎药相比，单克隆疗法的优势在于其功能类似于天然存在的抗体，能够通过正常的蛋白质降解途径消除，并通过肝脏或肾脏进行最小程度的代谢。这一突破性进展，使得索伦西亚和利布雷拉上市后销售额疯涨，也使得硕腾在抗炎药领域的市占率飞速提升——硕腾在抗炎药领域的市占率从2020年的28%提升至39%，2020-2022年该领域销售额年复合增长率高达39.6%。以上品类是属于细分产品，但也正因这种品类市场存在局限性，如果能够找准原有产品的命门，针对性革新，往往能够迅速改变市场格局，成为主导力量。颠覆性创新思路同样适用于大品类，比如疫苗。硕腾妙三多作为国内唯一获批的猫三联疫苗，长期垄断国内市场。但仔细研究后不难发现，受限于中美毒株同源性较低的问题，妙三多对于国内猫杯状病毒的免疫率并不好。以上海为例，妙三多采用的猫杯状毒株为美国255株，与上海流行毒株的核苷酸、氨基酸同源性较低，因此免疫率偏弱，从抽样数据来看，上海感染猫杯状病毒的病例中有71%都接种过妙三多。因此部分国产猫三联如瑞普生物、科前生物、农科院等，就是掐准了妙三多这个低免疫率的痛点，采用国内流行毒株进行颠覆性创新助推国产替代，利用政策风口迅速获批。创新成效显而易见。瑞普生物上市后短短一季度便实现了约1,200万元的销售额，覆盖了4,600家宠物医院，接种了超20万只猫。以史为鉴，国内宠物药也在驱虫药上进行配方迭代增加适应症；在猫三联疫苗上通过毒株本土化实现颠覆性创新。研发投入：不进则退，进则安国产宠物药似乎陷入了一个循环往复的怪圈：长期徘徊在创新的边缘，老药翻新、仿制药充斥市场，创新药寥寥无几。但仿制药又受制于代际差的桎梏，仿制药相对深度绑定渠道的先发者而言优势不大，故而仿制药市场发展又严重受限。一个不争的事实是，截至2021年，全球排名前十五的宠物医药企业无一例外都是创新药的生产商。对于国产企业想要在中短期快速切入产品壁垒相对较低的领域，依靠仿制路径确实是最行之有效的方式。如市场上销售业绩良好的国产驱虫药，如海乐妙，就是瑞士诺华公司猫内驱药妙巴的仿制品。同样，瑞普生物推出的驱虫新产品莫普欣，在成分上也与德国勃林格公司旗下的爱沃克产品颇为相似。仿制药确实可以在短时间内帮助企业获得市场份额和经济回报，但创新才是长期发展的重要立足点。在这一点上，硕腾同样是最好的范本。2022年，硕腾在全球的研发团队人数已达到1430人，这个规模不止是领先其主要竞争对手礼蓝，在全球动保行业中也是首屈一指。一方面，硕腾不遗余力地打造顶尖研发团队。现任研发总裁罗伯特·波尔泽，为普渡大学药物化学博士罗伯特波尔泽，为推进硕腾产品创新上做出了非常多贡献，比如跨物种、跨治疗领域的单克隆抗体疗法及驱虫产品组合创新，以及与科罗拉多州立大学在宠物过敏和皮肤病解决方案上的外部合作，都来自他的手笔。硕腾与美国高校、政府机构同样联系紧密。硕腾当前董事会的核心成员里德博士就是美国专业排名前十的普渡大学兽医学院院长，并且曾经担任过美国兽医学院协会主席并在美国国立卫生研究院及美国农业部多个委员会任职，丰富的行业资源，同样为硕腾的研发及新产品上市提供了不少助力。另一方面，在研发投入方面，硕腾更是不惜重金。根据Infogram披露的数据，2018年硕腾在动保领域的研发投入达到4.3亿美元，显著高于默沙东动保和礼蓝。高额投入同时，硕腾还会有意识通过外部收购来补全自身技术短板。2017年，硕腾通过收购Nexvet，成功填补了自身在生物制品研发方面的空白，使得硕腾成功在2020年推出了两款单克隆抗体抗关节炎药索伦西亚（猫）与利布雷拉（犬）。“高精尖团队+巨额研发投入”的策略促成了硕腾惊人的研发成果转化。——根据FDA数据，自1989年至2023年2月，硕腾的药物研发申请数量达551例，将竞争对手勃林格、默沙东等远远甩在身后。简言之：硕腾的打法就是“团队打造+研发投入+收购补缺”，以保障高研发成果转化。镜头切回国内，愈多企业开始认识到团队建设和研发投入的重要性。2018-2022年兽药行业研发投入力度持续加强，2022年研发费用占兽药产业总销售收入比重的11.4%，人员专业素质也在逐步提高，如科前生物选择与华中农业大学曹胜波教授团队合作去开发宠物疫苗产品，通过校企合作拔高了整体团队素质水平。渠道革新：以变应变，以通为赢硕腾的“95%直销+5%经销”混合渠道战略，精准且高效。2015年硕腾站在变革的十字路口。在此之前，硕腾的渠道基本以直销为主，产品直接面向全球70个国家。随着市场的变化和公司的成长，硕腾意识到，要想在竞争中保持领先，必须进行战略调整。2015年，硕腾做出了一个大胆而明智的决定：精简直销市场。经过深思熟虑，硕腾将直销市场从70个锐减至45个，这些市场集中了公司95%的营业额，是硕腾的业务重心所在。这一决策大举提高了运营效率，也使得硕腾能够更加专注于核心市场，深化与客户的直接联系，提供更为个性化和高效的服务。剩下那些销售额相对较低的25个市场，硕腾并没有放弃，而是采取了一种更为灵活的策略：转而采用经销商服务。通过与当地经销商的合作，硕腾能够更好地适应各个市场的文化和需求，同时也为这些市场的客户提供了更加便捷的服务。直销为主的模式下，使得销售人员的品牌忠诚度和目标性远超分销模式，且更利于产品的推广和客户关系的维护，同时也为公司在终端市场的控价提供了有力支撑。另外，还有一点值得提倡：硕腾的销售团队非常训练有素。硕腾的销售团队由销售代表和专业服务兽医组成。他们的销售代表，均接受过系统的免疫学、药理学、微生物学及产品相关培训，能够精准对接兽医客户，提供信息并推广产品和服务；他们的专业服务兽医，通常拥有高级兽医学学位，提供疾病管理咨询、培训及产品使用教学。并且硕腾对所有规模和区位的诊所采用单一价目表，并开发了ZoetisDirect线上平台供客户直接采购，保证对客户的直接触达和价格透明。结语硕腾凭借敏锐的市场洞察率先进军宠物医药领域，通过“针对性的产品策略+较高的研发成果转化+内外渠道的最优配置”，站在了如今的动保巅峰。猫三联疫苗只是一个缩影。国产力量崛起才刚刚开始。前人栽树好乘凉，希望从硕腾的成功之道中，能给国内玩家以启示。CMC议程已出！B证、CRO产品立无可立？会议邀请到了数十位企业决策层破解立项难题↓扫码查看所有议程推荐阅读

疫苗

2024-03-15

·PRNewswire

1.9 Million Doses of NexGard® PLUS (afoxolaner, moxidectin and pyrantel chewable tablets): Donated by Boehringer Ingelheim Cares Foundation to Aid Shelter Dogs in Need

DULUTH, Ga., March 15, 2024 /PRNewswire/ -- The Boehringer Ingelheim Cares Foundation, through its Product Donation Program, has made a significant contribution to animal shelters across the country. The Product Donation Program donates Boehringer Ingelheim medicines to approved nonprofit partners who distribute the medicines around the world where there is tremendous unmet need. Continue Reading The Foundation has donated 1.9 million doses of NexGard® PLUS chews, a delicious beef-flavored soft chew, designed to protect dogs from fleas and ticks, prevent heartworm disease, and treat and control roundworms and hookworms. Over 6 million doses of NexGard® PLUS chews have been sold since its launch in 2023. The Boehringer Ingelheim Cares Foundation has donated 1.9 million doses of NexGard® PLUS to animal shelters in need. Post this The donation, valued at $42.6 million, is part of Boehringer's ongoing commitment to support animal health and wellbeing. The company partnered with Greater Good Charities, a renowned organization dedicated to improving the health and well-being of people, pets and the planet, to distribute the products to animal shelters in need. This substantial donation will significantly impact the lives of countless dogs in shelters, providing them with essential protection against harmful parasites. Parasiticides play a crucial role in the adoption of shelter dogs by ensuring they are protected from parasites, thus enhancing their health and making them more appealing to potential adopters. "Boehringer Ingelheim is deeply committed to safeguarding the health and wellbeing of animals in shelters," said Randolph Legg, President and Head of Commercial Business, Boehringer Ingelheim Animal Health USA and board member of the Boehringer Ingelheim Cares Foundation. "Our mission is to ensure they receive the best care possible while they patiently wait for their forever homes. This donation is a testament to our commitment and we hope it will make a significant difference in the lives of animals in need." NexGard® PLUS Important Safety Information NexGard® PLUS (afoxolaner, moxidectin, and pyrantel chewable tablets) are for use in dogs only. The most frequently reported adverse reactions reported in clinical trials were diarrhea, vomiting, lethargy, and itching. Use with caution in dogs with a history of seizures or neurologic disorders. The safe use of NexGard® PLUS has not been evaluated in breeding, pregnant, or lactating dogs. Dogs should be tested for existing heartworm infection prior to starting a heartworm disease preventive. For more information, click here for full prescribing information, or visit NexGardPLUSClinic.com. About Boehringer Ingelheim Animal Health USA Boehringer Ingelheim Animal Health is working on first-in-class innovation for the prediction, prevention, and treatment of diseases in animals. For veterinarians, pet owners, producers, and governments in more than 150 countries, we offer a large and innovative portfolio of products and services to improve the health and well-being of companion animals and livestock. As a global leader in the animal health industry and as part of the family-owned Boehringer Ingelheim, we take a long- term perspective. The lives of animals and humans are interconnected in deep and complex ways. We know that when animals are healthy, humans are healthier too. By using the synergies between our Animal Health and Human Pharma businesses and by delivering value through innovation, we enhance the health and well-being of both. Learn more about Boehringer Ingelheim Animal Health USA at bi-animalhealth.com About Boehringer Ingelheim Cares Foundation Boehringer Ingelheim Cares Foundation is an independent nonprofit organization with a mission to strengthen the communities where our employees live and work by improving the health and well-being of people and animals, with a focus on helping the underserved. The programs we support align with our goals to improve access to healthcare, enhance STEM education, and strengthen the human-animal bond. NexGard® is a registered trademark of Boehringer Ingelheim Animal Health France, used under license. ©2024 Boehringer Ingelheim Animal Health USA Inc., Duluth, GA. All rights reserved. US-PET-0135-2024. SOURCE Boehringer Ingelheim

100 项与莫昔克丁相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D05084	莫昔克丁	P02CX03	DB11431

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
盘尾丝虫病	美国	Medicines Development for Global Health Ltd	2018-06-13

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
丝虫性象皮病	临床3期	刚果共和国	Medicines Development for Global Health Ltd	2021-05-03
丝虫性象皮病	临床3期	科特迪瓦	Medicines Development for Global Health Ltd	2021-05-03
盘尾丝虫病	临床3期	刚果共和国	Medicines Development for Global Health Ltd	2009-04-01
盘尾丝虫病	临床2期	加纳	Medicines Development for Global Health Ltd	2009-04-01
盘尾丝虫病	临床2期	利比里亚	Medicines Development for Global Health Ltd	2009-04-01
疥疮	临床1期	澳大利亚	Medicines Development for Global Health Ltd	2020-01-13
疥疮	临床1期	法国	Medicines Development for Global Health Ltd	2020-01-13
疥疮	临床1期	奥地利	Medicines Development for Global Health Ltd	2020-01-13
盘尾丝虫病	临床1期	利比里亚	Medicines Development for Global Health Ltd	2009-04-01
盘尾丝虫病	临床1期	加纳	Medicines Development for Global Health Ltd	2009-04-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04848688 (StrongMoxi_KH, CTgov)	临床3期	类圆线虫病	332	Placebo+Moxidectin 2 mg (Moxidectin)	鏇夢膚簾獵壓鹹齋鏇選(夢鬱網淵遞觸鹽範襯醖) = 鹽願鹹壓醖築窪糧積壓願簾鏇餘蓋餘醖顧鏇簾 (艱簾築衊鬱蓋繭蓋餘製, 膚廠顧糧製齋鏇遞觸淵 ~ 製窪積鹽壓鹹積鹹齋鬱) 更多	-	2024-01-24
				Placebo+Ivermectin 3 mg (Ivermectin)	鏇夢膚簾獵壓鹹齋鏇選(夢鬱網淵遞觸鹽範襯醖) = 顧網範廠簾鏇蓋襯繭衊願簾鏇餘蓋餘醖顧鏇簾 (艱簾築衊鬱蓋繭蓋餘製, 製壓築衊醖鏇蓋鬱網窪 ~ 憲鏇夢廠鹹壓壓簾鹹艱) 更多
NCT03905265 (CTgov)	临床2期	疥疮	22	Moxidectin Oral Product (Moxidectin 2 mg)	壓蓋網積鹹簾艱蓋襯鏇(網築醖網鏇夢壓繭鏇築) = 餘鬱廠願網鬱醖憲願齋夢製鹹築齋壓願餘鑰窪 (鑰鏇願艱積蓋繭築簾選, 衊製鏇構餘願鹹夢憲窪 ~ 廠獵壓繭繭觸顧糧鹹構) 更多	-	2023-09-22
				Moxidectin Oral Product (Moxidectin 8 mg)	壓蓋網積鹹簾艱蓋襯鏇(網築醖網鏇夢壓繭鏇築) = 夢廠艱顧鹽觸淵簾範鹽夢製鹹築齋壓願餘鑰窪 (鑰鏇願艱積蓋繭築簾選, 醖構顧壓醖壓願襯顧膚 ~ 顧艱廠簾窪鑰顧網構製) 更多
NCT04410406 (Pubmed \| PLoS Negl Trop Dis)	临床3期	丝虫性象皮病 Wuchereria bancrofti microfilaremia	-	ivermectin + albendazole	(獵醖鑰襯構製窪窪齋遞) = Four participants had transient Grade 3 hematuria after treatment (3 after IDA and 1 after IA) 廠積積壓遞鑰醖積衊餘 (顧齋範餘鑰積積積衊鏇 ) 更多	积极	2023-09-18
				moxidectin + albendazole
NCT04726969 (CTgov)	临床3期	鞭虫病 \| 蛔虫病 \| 钩虫感染	255	Albendazole 400 mg Oral Tablet+Moxidectin 2 mg Oral Tablet (Arm A: Moxidectin and Albendazole)	願蓋鏇糧鏇廠鏇醖觸簾(顧顧築遞壓窪艱積構範) = 積衊鏇鬱夢顧願淵糧夢餘憲窪淵製糧築鬱鏇願 (餘夢簾廠遞繭膚鏇醖製, 獵簾範構選範鏇築積鑰 ~ 糧蓋製憲鬱積製襯顧鹹) 更多	-	2023-02-02
				Albendazole 400 mg Oral Tablet (Arm B: Albendazole)	願蓋鏇糧鏇廠鏇醖觸簾(顧顧築遞壓窪艱積構範) = 構觸遞艱構廠膚範鏇窪餘憲窪淵製糧築鬱鏇願 (餘夢簾廠遞繭膚鏇醖製, 膚範鬱淵窪窪構網構鬱 ~ 壓觸選繭簾襯築鹹積廠) 更多
NCT00790998 (Pubmed)	临床3期	盘尾丝虫病	1,497	Moxidectin 8 mg	夢繭膚廠獵壓壓鏇膚膚(觸繭蓋簾餘鹹憲蓋鏇鹹) = 鏇築顧餘壓積網簾鬱願獵繭繭鑰鏇觸築觸淵鑰 (蓋鬱襯獵膚顧繭餘簾鹹 )	积极	2022-04-27
				Ivermectin 150 μg/kg	夢繭膚廠獵壓壓鏇膚膚(觸繭蓋簾餘鹹憲蓋鏇鹹) = 醖願蓋窪醖壓蓋鏇簾醖獵繭繭鑰鏇觸築觸淵鑰 (蓋鬱襯獵膚顧繭餘簾鹹 )
NCT04056325 (Pubmed \| Clin Pharmacokinet)	临床2期	类圆线虫病	96	Moxidectin	(繭窪蓋艱鹽壓壓製壓築) = 鹽蓋襯獵憲夢簾廠廠糧齋壓鹹構願淵齋鹹壓積 (廠蓋醖餘構選窪選衊夢, 3.63 ~ 5.39) 更多	-	2021-07-23
NCT03012828 (CTgov)	临床1期	眼盘尾丝虫病	60	Moxidectin (Moxidectin 4mg)	襯窪糧獵鏇願顧鹹鑰鏇(齋艱餘築選鹽衊構鹽網) = 鹹衊築淵製膚構鏇鑰構餘壓簾獵鏇膚鏇積鬱廠 (顧襯鏇醖繭糧鹽構艱網, 範淵壓製製觸糧願構願 ~ 積積餘遞醖鏇鬱鏇糧廠) 更多	-	2019-03-14
				Moxidectin (Moxidectin 8mg)	襯窪糧獵鏇願顧鹹鑰鏇(齋艱餘築選鹽衊構鹽網) = 餘艱構製廠廠餘餘淵範餘壓簾獵鏇膚鏇積鬱廠 (顧襯鏇醖繭糧鹽構艱網, 廠衊餘醖範顧膚觸積膚 ~ 範醖齋膚構襯構齋遞網) 更多
NCT00300768 (Pubmed \| PLoS Negl Trop Dis)	临床2期	盘尾丝虫病	172	8 mg moxidectin	(繭鹹積淵憲網衊廠製糧) = 鑰鬱製製憲壓糧觸鏇夢廠鏇壓鹹網夢選選網蓋 (襯糧積繭鏇鏇膚願齋醖 ) 更多	-	2014-06-01
				150 µg/kg ivermectin	(繭鹹積淵憲網衊廠製糧) = 憲蓋壓壓蓋鹹鑰淵製網廠鏇壓鹹網夢選選網蓋 (襯糧積繭鏇鏇膚願齋醖 ) 更多